Biossil Valuation, Funding & Investors

Biossil is valued at $1B as of September 2026.

Last Biossil valuation

$1B

Undisclosed stage · Sep 2026

Last Biossil funding round

$153M

Undisclosed stage · Sep 2026

Cumulative funding Biossil raised

$223M

across 2 funding rounds

Key investors in Biossil

  • Founders Fund
  • Quiet Capital
  • Golden Ventures
  • Panache Ventures
  • Modern Capital
  • OpenAI

Biossil Overview

About Biossil

Biossil is an applied AI drug discovery platform that develops specialized treatments for individual patients.


Founded

2023

HQ

CanadaToronto

Website

biossil.co

Status

Privately held

Valuation

$1B (Sep 2026)

Biossil Valuation

Biossil is currently valued at $1B, based on its undisclosed-stage round in September 2026. Read the announcement ↗

The $153M round was led by OpenAI Startup Fund, with participation from Panache Ventures, Modern Capital, Founders Fund, Abu Dhabi Investment Council, Duke University and 2 other investors.

Biossil valuation by funding round

Biossil valuation by funding round
DateStageValuation
Sep 2026Undisclosed stage$1B

Biossil Funding History

Biossil has raised a total of $223M across 2 funding rounds.

Biossil's first fundraising round was a $70M undisclosed-stage round in April 2026. The most recent completed round was a $153M undisclosed-stage round in September 2026.

Biossil funding rounds

Biossil funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Sep 2026Undisclosed stageOpenAI Startup Fund (lead); Panache Ventures; Modern Capital; Founders Fund; Abu Dhabi Investment Council; Duke University; Quiet Capital; Golden Ventures$153M$1BOpenAI’s Startup Fund led Biossil’s September 2026 all-equity financing of $153 million at a $1 billion valuation, with participation from Founders Fund, Quiet Capital, Modern Capital, Golden Ventures, Panache Ventures, Duke University’s endowment fund, and Abu Dhabi Investment Council. The round was used to expand Biossil’s clinical development capacity and to buy additional drug candidates for its pipeline, supporting its model of acquiring failed or discontinued drug assets and attempting to revive them with artificial intelligence. Biossil is a Toronto-based biotech company focused on rescuing abandoned drug candidates and advancing them through clinical development using AI-assisted analysis.
Apr 2026Undisclosed stage137 Ventures; Panache Ventures; Staircase Ventures; OpenAI; Modern Capital; Founders Fund; DRI Healthcare Trust; Quiet Capital; Golden Ventures$70M-Toronto-based biotech startup Biossil raised approximately $70 million USD in equity funding, exiting stealth mode in April 2026. Backers include OpenAI Startup Fund, Founders Fund, Modern Capital, Staircase Ventures, Golden Ventures, Panache Ventures, Quiet Capital, 137 Ventures, and DRI Healthcare. The company has not raised debt but evaluates off-balance-sheet funding sources. Biossil acquires drug candidates discarded by competitors after clinical trial failures and revives them using AI to give failed medicines a second chance. This strategy leverages artificial intelligence for innovative drug development. Biossil operates in the biotech sector, focusing on rescuing abandoned pharmaceutical assets to accelerate development timelines.

Who has invested in Biossil?

12 investors have backed Biossil across its funding rounds, including Founders Fund, Quiet Capital, Golden Ventures, Panache Ventures, Modern Capital and OpenAI.

Lead investors include OpenAI Startup Fund.


Biossil Investors

Investors in Biossil by funding rounds participated
InvestorHQRoundsRoleFirst check
Panache VenturesCanadaMontreal2ParticipantApr 2026
Modern CapitalUnited StatesCharleston, SC2ParticipantApr 2026
Founders FundUnited StatesSan Francisco, CA2ParticipantApr 2026
Quiet CapitalUnited StatesSan Francisco, CA2ParticipantApr 2026
Golden VenturesCanadaToronto2ParticipantApr 2026
OpenAI Startup FundUnited StatesSan Francisco, CA1LeadSep 2026
137 VenturesUnited StatesUnited States1ParticipantApr 2026
Staircase VenturesCanadaToronto1ParticipantApr 2026
OpenAIUnited StatesSan Francisco, CA1ParticipantApr 2026
Abu Dhabi Investment CouncilUAEAbu Dhabi1ParticipantSep 2026

This data is available for Pro users. Sign up to see all 12 Biossil investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Biossil Competitors

Biossil competitors include listed companies like Arcs Co and Alto Neuroscience, and private ones like Collate, Altana, Augury and Beamery.

Public and private companies comparable to Biossil
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
CollateUnited StatesSan Francisco, CAPrivate--$1B-
Arcs CoJapanJapanPublicly listed$4B$183M$1.2B0.2x
AltanaUnited StatesNew York City, NYPrivate-$564M$1B-
AuguryUnited StatesNew York City, NYPrivate$100M-$1B-
BeameryUnited KingdomLondonPrivate--$1B-
Alto NeuroscienceUnited StatesUnited StatesPublicly listed-($67M)$1B-

Biossil Public Comps

Biossil is still privately-owned, but its public comps include Alto Neuroscience, Pacira BioSciences, iFLYHealth, Kissei Pharmaceutical, MoonLake, Oscotec, Vetoquinol, Cullinan Therapeutics, SPIMACO - ADDWAEIH and Monte Rosa Therapeutics.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Alto Neuroscience-($67M)--(11.7x)(7.5x)
Pacira BioSciences$726M$100M1.6x1.5x11.6x6.3x
iFLYHealth$137M($7M)7.6x6.1x(148.8x)2071.1x
Kissei Pharmaceutical$619M$136M1.1x1.1x5.0x15.6x
MoonLake-($220M)--(2.5x)(2.3x)
Oscotec$74M$39M11.8x14.3x22.3x29.3x
Vetoquinol$597M$126M1.3x1.3x6.0x5.9x
Cullinan Therapeutics-($242M)-69.2x(2.7x)(3.2x)

This data is available for Pro users. Sign up to see all Biossil competitors and their valuation data.

Start Free Trial

Common questions about Biossil

When was Biossil founded?Biossil was founded in 2023.
Where is Biossil headquartered?Biossil is headquartered in Toronto, Canada.
Is Biossil publicly listed?No, Biossil is a private, VC-backed company.
What is Biossil's valuation?Biossil was last valued at $1B in its undisclosed-stage round in September 2026.
How much funding has Biossil raised?Biossil has raised $223M across 2 funding rounds.
What was Biossil's last funding round?Biossil's last funding round was a $153M undisclosed-stage round in September 2026, led by OpenAI Startup Fund.
Who are Biossil's investors?Biossil's investors include Panache Ventures, Modern Capital, Founders Fund, Quiet Capital, Golden Ventures, OpenAI Startup Fund, 137 Ventures, Staircase Ventures, OpenAI, Abu Dhabi Investment Council and 2 others.
Which companies are comparable to Biossil?Companies comparable to Biossil include Collate, Arcs Co, Altana, Augury, Beamery and Alto Neuroscience.

See companies similar to Biossil

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial